BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for March:

March 7-9:
Cowen & Co. Annual Healthcare Conference

March 9-13:
National Comprehensive Cancer Network Annual Meeting (NCCN)

March 10:
Human Genome Sciences ( HGSI): FDA drug approval decision date for Benlysta in lupus.
Dendreon ( DNDN): FDA approval decision for expansion of Provenge manufacturing capacity at New Jersey facility.

March 18-22:
American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

March 24-27:
American Academy of Pain Medicine (AAPM) meeting.

March 26:
Bristol-Myers Squibb ( BMY - Get Report): FDA drug approval decision date for Yervoy in melanoma.

March 30 - April 3:
European Association for the Study of the Liver (EASL) annual meeting.

Other potential biotech events in March:

Cell Therapeutics ( CTIC - Get Report): Outcome of FDA appeal meeting for pixantrone in aggressive non-Hodgkin's lymphoma

A.P. Pharma ( APPA): Meeting with FDA to discuss requirements for resubmission of APF530 for chemotherapy-induced nausea following last year's rejection letter.

Achillion Pharmaceuticals: ( ACHN) Top-line results from 28-day, phase IIa study of hepatitis C drug ACH-1625.

Celgene ( CELG - Get Report): Top-line results from phase II study of amrubicin in small-cell lung cancer.

Corcept Therapeutics: ( CORT - Get Report) FDA approval filing for Corlux in Cushing's syndrome.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.